文献类型：期刊文献

英文题名：A pan-cancer analysis of the prognostic value of long non-coding RNA LINC00662 in human cancers

作者：Zhang, Guangming[1,2,3,4];Wu, Bin[1,2,3,4];Fu, Liangyin[1,2,3,4];Liu, Bin[4,5];Han, Xiaoyong[6];Wang, Jie[1];Zhang, Yipeng[1];Yu, Miao[4];Ma, Haizhong[4,5];Ma, Shixun[4,5];Cai, Hui[1,2,3,4]

第一作者：Zhang, Guangming

通信作者：Cai, H[1];Cai, H[2];Cai, H[3];Cai, H[4]

机构：[1]Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou, Peoples R China;[2]Gansu Prov Hosp, Clin Med Ctr, Dept Gen Surg, Lanzhou, Peoples R China;[3]Key Lab Mol Diagnost & Precis Med Surg Oncol Gansu, Lanzhou, Peoples R China;[4]Gansu Prov Hosp, Lanzhou, Peoples R China;[5]Lanzhou Univ, Clin Med Coll 1, Lanzhou, Peoples R China;[6]Ning Xia Med Univ, Yinchuan, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Clin Med Ctr, Dept Gen Surg, Lanzhou, Peoples R China;[3]corresponding author), Key Lab Mol Diagnost & Precis Med Surg Oncol Gansu, Lanzhou, Peoples R China;[4]corresponding author), Gansu Prov Hosp, Lanzhou, Peoples R China.|[10735]甘肃中医药大学;

年份：2022

卷号：13

外文期刊名：FRONTIERS IN GENETICS

收录：;Scopus(收录号：2-s2.0-85144548029);WOS:【SCI-EXPANDED(收录号:WOS:000902027200001)】；

基金：This study was supported by grants from the 2021 Central-Guided Local Science and Technology Development Fund (ZYYDDFFZZJ-1); Gansu Key Laboratory of molecular diagnosis and precision treatment of surgical tumors (18JR2RA033); Key talent project of Gansu Province of the Organization Department of Gansu provincial Party committee (2020RCXM076); Key Laboratory of gastrointestinal cancer diagnosis and treatment of National Health Commission (2019PT320005); Lanzhou talent innovation and Entrepreneurship Project (2016-RC-56); Gansu University of Chinese Medicine Postgraduate "Innovation Fund" project (2022CX52); Gansu Province Excellent Doctor Fund Project (22JR5RA649).

语种：英文

外文关键词：LINC00662; meta-analysis; cancers; prognosis; bioinformatics

摘要：Background: Numerous studies have revealed that the long non-coding RNA LINC00662 is irregularly expressed in various cancers, as well as is correlated with cancer development and progression. Nevertheless, the clinical value of LINC00662 remains controversial. Hence, we explored the correlation of LINC00662 with cancer prognosis through meta-analysis and bioinformatics analysis.Methods: From the beginning through 12 March 2022, we searched for correlational studies on Web of Science, Embase, PubMed and The Cochrane Library. We used pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) to determine the significance of studies on survival outcomes and clinicopathological aspects in human cancers. Additionally, the Gene Expression Profiling Interactive Analysis (GEPIA) database was employed to confirm our findings.Results: Our meta-analysis of 14 studies comprising a total of 960 cancer patients revealed that LINC00662 overexpression was correlated with poor overall survival (HR = 1.91, 95% CI 1.49-2.45, p < 0.001) in cancer patients and relapse-free survival (HR = 2.12, 95% CI 1.19-3.76, p = 0.010) in hepatocellular carcinoma patients. The correlation between LINC00662 and OS was further supported by the results of subgroup analyses according to cancer type, follow-up time, HR availability, and NOS score. In addition, LINC00662 overexpression predicted advanced tumor stage (OR = 4.23, 95% CI 2.50-7.17, p < 0.001), larger tumor size (OR = 1.49, 95% CI 1.11-1.99, p = 0.008), earlier lymph node metastasis (OR = 2.40, 95% CI 1.25-4.59, p = 0.008), and earlier distant metastasis (OR = 4.78, 95% CI 2.57-8.88, p < 0.001). However, there were no statistically significant differences in age (OR = 1.16, 95% CI 0.90-1.51, p = 0.246), gender (OR = 1.10, 95% CI 0.79-1.53, p = 0.578), or differentiation grade (OR = 1.53, 95% CI 0.71-3.33, p = 0.280).Conclusion: LINC00662 expression upregulation is associated with poor prognosis and advanced clinicopathological features in patients with multiple tumors. LINC00662 may serve as a biomarker for the diagnosis and treatment of patients with tumors.